3 ms·
Next up is the lp(a) lowering drugs still in trials.
by JoshGlazebrook 3mo ago
Next up is the lp(a) lowering drugs still in trials.
- nwah1 3mo agoYes, exciting stuff. Not to mention the gene-therapy version of the same PCSK9 inhibition pathway called VERVE-102 which Eli Lilly is putting through human trials as we speak. I imagine that stacking the LP(a) antisense therapy with a PCSK9 inhibitor, and/or a statin or Nexlizet would probably lower odds of heart disease death by two to three orders of magnitude. But I guess there isn't solid mortality data to say for sure.